Results 91 to 100 of about 2,979 (199)

Identifying High‐Risk Medications for Drug‐Induced Dystonia: A 20‐Year Retrospective Real‐World Pharmacovigilance Study Based on FAERS

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Drug‐induced dystonia is a serious, potentially disabling adverse event (AE) associated with certain medications. Despite its clinical relevance, the existing literature is largely limited to case reports or analyses of individual drugs, and a systematic evaluation of medications implicated in dystonia remains lacking. This
Chunhua Chen, Xiaobin Lin, Yi Yang, Jiajia Yan, Jingxiu Chen, Yifan Zheng, Jia Li   +6 more
wiley   +1 more source

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

BMC Psychiatry, 2017
Background Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse.
Henry A. Nasrallah, Willie Earley, Andrew J. Cutler, Yao Wang, Kaifeng Lu, István Laszlovszky, György Németh, Suresh Durgam   +7 more
doaj   +1 more source

Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer

, 2018
Multidrug resistance (MDR) is a continuing clinical problem that limits the efficacy of chemotherapy in cancer. The over expression of the ATP-binding cassette (ABC) family G2 (ABCG2) transporter is one of the main mechanisms that mediates MDR in cancer.
Noor Hussein, Haneen Amawi, Chandrabose Karthikeyan, Angelique Nyinawabera, Atul Vij, Charles R. Ashby, Amit K. Tiwari, Vishwa M. Khare   +7 more
core   +1 more source

Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder

ClinicoEconomics and Outcomes Research
Prakash S Masand,1 Mousam Parikh,2 Jamie T Ta,2 Sally W Wade,3 Filmon Haile,2 Susannah Ripley,4 Enrico Zanardo,5 Colleen S Spencer,4 François Laliberté,4 Nadia Nabulsi2 1Duke-NUS, Singapore; 2AbbVie, North Chicago, IL, USA; 3Wade Outcomes Research and ...
Masand PS, Parikh M, Ta JT, Wade SW, Haile F, Ripley S, Zanardo E, Spencer CS, Laliberté F, Nabulsi N   +9 more
doaj  

Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting

Annals of General Psychiatry
Background Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data ...
Christoph U. Correll, Andrew J. Cutler, François Laliberté, Guillaume Germain, Sean D. MacKnight, Julien Boudreau, Sally W. Wade, Nadia Nabulsi, Huy-Binh Nguyen, Mousam Parikh   +9 more
doaj   +1 more source

The novel atypical antipsychotic cariprazine demonstrates dopamine D₂receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

, 2018
International audienceAbstract Aim Cariprazine, a dopamine D 3 ‐preferring D 3 /D 2 receptor partial agonist, is FDA approved for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder.
Delcourte, Sarah, Rovera, Renaud, Sarah Delcourte, Béla Kiss, Nika Adham, Charles R. Ashby, Ashby, Charles, Renaud Rovera, Kiss, Béla, Farkas, Bence, Bence Farkas, Adham, Nika, Haddjeri, Nasser, Nasser Haddjeri   +13 more
core   +1 more source

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation

Neuropsychiatric Disease and Treatment, 2019
Christoph U Correll,1–3 Rakesh Jain,4 Jonathan M Meyer,5 Antonia Periclou,6 Timothy Carrothers,6 Ágota Barabássy,7 Mehul Patel,8 Willie Earley91Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY ...
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W   +7 more
doaj  

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia

Neuropsychiatric Disease and Treatment, 2022
Larry Culpepper,1 Eduard Vieta,2 Deanna L Kelly,3 Mehul D Patel,4 Balázs Szatmári,5 Arlene Hankinson,4 Willie R Earley4 1Boston University School of Medicine, Boston, MA, USA; 2Hospital Clinic, Institute of Neuroscience, University of ...
Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR   +6 more
doaj  

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices [PDF]

, 2019
Background and purpose: Gamma oscillations are fast rhythmic fluctuations of neuronal network activity ranging from 30 to 90 Hz that establish a precise temporal background for cognitive processes such as perception, sensory processing, learning, and ...
Meier, Maria A., Adham, Nika, Lemercier, Clement E., Kulisch, Christoph, Lendvai, Balázs, Gerevich, Zoltan, Kiss, Béla   +6 more
core   +1 more source

The role of dopamine D 3 receptors in the mechanism of action of cariprazine

, 2019
Cariprazine is a new atypical antipsychotic drug (APD) with a unique pharmacodynamic profile, different from both typical and atypical APDs. Specifically, cariprazine acts as a partial agonist at the dopamine (DA) D 2 and D 3 receptors and serotonin 5-HT
Calabrese F., Riva M. A., Racagni G., Tarazi F. I.   +3 more
core   +1 more source